Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes.
In an attempt to develop a quantitative assay for supravesicular structures (SVS) - such as aggregates, fused liposomes or solid lipid particles - in liposome preparations, forward vs. side scattering of liposomal doxorubicin (Doxil/Caelyx) was analyzed by flow cytometry. Based on calibration with fluorescent latex beads, the size resolution was between about 500 and 1000 nm. Caelyx, just as structurally matched empty liposomes (Doxebo) produced dot plots clearly distinguishable from background, suggesting the presence of SVS in the above size region. A comparison of gated areas on the scattergrams obtained for different Caelyx preparations showed differences between current and expired samples, implying that SVS formation may be storage-time-dependent. Incubation of doxorubicin with Doxebo in a free drug and lipid concentration range that corresponds to that in Caelyx also led to varying SVS patterns, raising the possibility that free doxorubicin in Caelyx might contribute to SVS formation. Dynamic light scattering and transmission electron microscopic analysis of liposomes following gaiting and sorting of >500 nm particles from Caelyx confirmed the presence of SVS, providing independent evidence for their stable existence. Based on a rough estimation, the amount of SVS in Caelyx is some 60 billionth part of all liposomes. These observations raise the possibility that the presence of an exceedingly small fraction of >500 nm particles may be an intrinsic property of PEGylated small unilamellar liposomes, and that the described FACS analysis may be developed further as a quality assay for liposomal homogeneity.
Nanomedicine Research and Education Center, Semmelweis University and Bay Zoltán Ltd., Budapest, Hungary.
Gergely
G
Milosevits
Zoltán
Z
Rozsnyay
Gergely T
GT
Kozma
János
J
Milosevits
Gyöngyvér
G
Tömöry
Hermina
H
Robotka
László
L
Rosivall
János
J
Szebeni
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000737:chemistry; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry; D004355:Drug Stability; D005434:Flow Cytometry; D008081:Liposomes / Q000737:chemistry* / Q000648:ultrastructure*; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry*
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin